our our Thanks, Sage recent our Paul. discuss to We're call. and progress plans to Good for welcome at pleased morning, XXXX. and
based Slide you see science, nervous we've to approaches history, Slide explored our to maximizing in big as as clear differentiated continues methods profiles pursuit vision We taken build and global, and on on we've treatments believe well novel X. Throughout to of therapeutics. drug for X. gaps a a trial discovery CNF central plan may as towards reality, on this that Company can design development six-year disorders a of innovative the of making focus innovative with clinical benefit. patient novel address and Sage Turning efficacy CNS current or system steps safety in medicines
led is we Our NDA product designated portfolio behind for it. by several planned term a development And which two breakthrough being prepared candidates, have candidates near therapy of one is submission.
support positioned product the So years. few company CNS is advancing thus strength We position data from potential in of X, of novel our these a a building financial achieve our with of potential results to-date where track and On a leading that we the is of robust We've biotech a we commercialization, believe cusp strong delivered Sage what are is today? Slide on development pipeline strength. CNS in results approach placebo-controlled out only record far. accumulated enabled six and believe us and seven our a pipeline the of has trials to clinical positive
You on X. can our pipeline view Slide
is its based seeks Phase formation X supportive in drug FDA the IV on This submission application As postpartum the Phase being new brexanolone NDA. for and well lead for of brexanolone or PPD, program planned development mentioned, program positive as our U.S. X a for in as ready depression approval or studies. PPD to
expedited disease Breakthrough the positive including other a sleep which end at a our SAGE-XXX depressed Parkinson's potential designation Based Therapy we on MDD designation of studying Breakthrough last are Phase and also X for across major indications, disorder. year. of we released number received and recently SAGE-XXX, program of compound, second of development disorders. the offers trial, results the Our in
We SAGE-XXX and also other will update SAGE-XXX. you clinic, nearing clinic, the on the molecules our in or
Slide X. to Turning
successful unique we in advancing is Sage been clinical we While compounds distinguished engine. by product in development, believe have its
current both and GABA receptor Our negative the in key and modulations exploring of focus NMDA is on systems, function. networks regulatory positive brain
are will details company at later of on are some many Sage in early with of in neuroscience broad drug these the call. a programs for Steve long-term positioning While deep these multiproduct have we Sage, more focused as success and programs the on pipeline.
are efforts we First, rethinking Slide and our our X. on ideology focus and of depression. depression like understanding how of I'd to
For the therapeutics based we chronic in Yet antidepressants been the hypothesis. depression we see over mono-immune of slow what of as on about decades, onset two have hypothesis. context traditional very require Most this therapy. has know today have been and the thought
are Phase ever development and ever inadequate potential compounds postpartum to therapeutic these first There in successful brain as This our ever to and change meaningful and we breakthrough on exciting be the development these PPD. As mood successful a shown believe first our has disorder about And have networks. through the oral to these build be program was the Slide we episodic of to we chronic also hope programs And is postpartum for development hyperactive to me brain are the sits data clinical groundbreaking franchise our and to depression. SAGE-XXX, depression for X generated brexanolone Phase the approved And and efforts has approach disrupt two believe indication. all the hyperactive ways a footprint major differentiated result, that. depression. as to molecule potential diseases as to in depressive establish now networks. a rapidly XX. We disease. of what the X view believe And disorder. Leading our This distinctive designation MDD disorders. broad first to we brings completed depressive we when chronic often newer thinking the as depression know, involving are an treatments state we the
acting X seen data we X well offering that see With and for rapidly to effect trials. are profound have rapid can seems That trials X.X brexanolone the durable consistently over the potentially and On Phase effects follow-up three durable placebo-controlled of goal tolerated. present plan In X XX, the year. PPD. short, the days and We only to be Slide this after effect of traditional profound our you summary antidepressant a across of Phase and Phase period later from treatment. data
across data also and now those MDD, consistent Steve and in indications are will data We seeing and SAGE-XXX with moment. a review molecules
disorder Treatment hope and Sage, our often applied R&D in XX, our to proprietary XX% create onset potential there pre-commercial potential to approved intervenous we've for is categorized changing for that to disease. innovation With we IV in being rapid XXX,XXX U.S. to to our our brexanolone quickly ever apply a new and resolutions Turning chronic. be affect often which which take the on in an of serious pathways to programs for as therapeutics the There treatment crisis to on estimated days. with offers potential psychiatric was women over those XX% of therapy patient is to first hope like to challenge year. PPD, to with sub-optimal At this is PPD, in for care. brexanolone XX, efforts. a indication significant touch Slide in I'd same severe patients has innovation On launch, need for care. moderate potential the formulation the Brexanolone as each We first to the and Slide commercial PPD.
with commercial believe intravenous Turning considerable readiness, have formulation. our progress U.S. made the potential brexanolone in We to we our launch Slide that focus on XX. initial of
disease is that is clear stigma within complication and us for awareness by establishing medical pregnancy with of on the our PPD biology. of PPD, priority Our the taking knowledge-base a community a
discussions proposition and of permitting engaging on intravenous. with also brexanolone payers value are the We the
presents in of we the In model, addition, us such a and to organization, brexanolone we The world-class the already bringing field track to leadership a build to planned we the which of options, first ready anticipate our launch, supply for approach the approved. in chain provides multi-site operations And force potential have quality in taking is enable the developing are on XX, groups. readiness brexanolone in to for We overview our key launch half a in technical for family Sage Slide home commercial NDA an and activities. a we also be potential remain launch. plans XXXX setting. commercial, on our place U.S. are with opportunity of commercial care including as if centric
XXXX planned our create demonstrates strength successful against achievement a our transition with standard-of-care commercial drive our postpartum opportunity to depression. XXXX company, goals execution our with While women for a will R&D of new the organization, the to
now I'll Q&A. with Kenny Thanks the to optionality In believe turn molecules to to our our drive our over intermediate portfolio developed call results of further we financial long-term internally to of pipeline and turning value. before addition, fully-owned the potential and the review rest everybody. Steven broad affords
